Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TearsAgain is a family of over-the-counter (OTC) eye care products, including eye sprays and drops, marketed by the Swedish company Circius Pharma. It is primarily indicated for the relief of dry eye symptoms and blepharitis. The eye spray formulation is particularly notable for its use of liposomes (phospholipids) that integrate into and stabilize the lipid layer of the tear film. This action helps to reinforce the eye's natural protective barrier, significantly reducing the evaporation of the aqueous layer of the tears, which is a leading cause of evaporative dry eye. The product is designed for easy application to closed eyelids, from where the liposomes migrate to the tear film to provide long-lasting moisturization and relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TearsAgain.